Order Article Reprints

Diallo K, Degboé Y, Baron M, Bellin-Robert A, Boyer J-F, Ruyssen-Witrand A, Constantin A, Rauwel B, Cantagrel A, Davignon J-L. Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation. Diagnostics. 2025; 15(10):1232. https://doi.org/10.3390/diagnostics15101232

Diallo, Katy, Yannick Degboé, Michel Baron, Anaïs Bellin-Robert, Jean-Frédéric Boyer, Adeline Ruyssen-Witrand, Arnaud Constantin, Benjamin Rauwel, Alain Cantagrel, and Jean-Luc Davignon. 2025. "Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation" Diagnostics 15, no. 10: 1232. https://doi.org/10.3390/diagnostics15101232

Diallo, K., Degboé, Y., Baron, M., Bellin-Robert, A., Boyer, J.-F., Ruyssen-Witrand, A., Constantin, A., Rauwel, B., Cantagrel, A., & Davignon, J.-L. (2025). Predicting Clinical Response to Monoclonal TNF Inhibitors in Rheumatoid Arthritis: A Transcriptomic Approach Based on Transmembrane TNF Reverse Signaling and Nrf2 Activation. Diagnostics, 15(10), 1232. https://doi.org/10.3390/diagnostics15101232